Over the past year there were no insider purchases at Amneal Pharmaceuticals, Inc.. Five insiders sold roughly $9.8 million instead.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
Big money check: 308 institutions held AMRX as of Q2 2026, and more funds bought than sold. Quarter by quarter: 2 quarters in a row of net selling by insiders. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Kiely John | Director | Sell | 50,000 | $17.64 | $882K | SEC |
| Aug 13, 2026 | Shah Nikita | President | Sell | 146,403 | $17.51 | $2.6M | SEC |
| Aug 13, 2026 | Daly Jason B. | Executive Officer | Sell | 6,613 | $17.70 | $117K | SEC |
| Aug 13, 2026 | Daly Jason B. | Executive Officer | Sell | 210,000 | $17.40 | $3.7M | SEC |
| May 12, 2026 | Autor Deborah M. | Director | Sell | 34,819 | $12.94 | $451K | SEC |
| Nov 19, 2025 | Nark Ted C | Director | Sell | 50,000 | $11.72 | $586K | SEC |
| Nov 14, 2025 | Shah Nikita | President | Sell | 131,856 | $11.92 | $1.6M | SEC |
| Aug 28, 2025 | Kiely John | Director | Sell | 32,000 | $9.23 | $295K | SEC |
| Aug 25, 2025 | Shah Nikita | President | Sell | 6,340 | $9.50 | $60K | SEC |
| Aug 25, 2025 | Shah Nikita | President | Sell | 114,492 | $9.66 | $1.1M | SEC |
| Aug 22, 2025 | BOYER ANDREW S | President | Sell | 279,244 | $9.38 | $2.6M | SEC |
| Aug 15, 2025 | Shah Nikita | President | Sell | 71,694 | $9.29 | $666K | SEC |
| Aug 15, 2025 | Konidaris Tasos | CFO | Sell | 219,159 | $9.43 | $2.1M | SEC |
| Aug 15, 2025 | Konidaris Tasos | CFO | Sell | 119,206 | $9.30 | $1.1M | SEC |
| Aug 15, 2025 | Konidaris Tasos | CFO | Sell | 161,365 | $9.22 | $1.5M | SEC |
In the last 12 months Amneal Pharmaceuticals, Inc. insiders made open-market purchases worth about $0 and sales worth about $9.8 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in AMRX was filed on 2026-08-14.
308 investment managers reported holding AMRX in SEC Form 13F filings for Q2 2026.
No congressional trades in AMRX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).